Santen Pharmaceutical Co., Ltd. (TYO: 4536)
Japan
· Delayed Price · Currency is JPY 1,544.50
-4.50 (-0.29%)
Dec 20, 2024, 3:45 PM JST
Santen Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 302,563 | 301,965 | 279,037 | 266,257 | 249,605 | 241,555 | Upgrade
|
| Revenue Growth (YoY) | 2.24% | 8.22% | 4.80% | 6.67% | 3.33% | 3.22% | Upgrade
|
| Cost of Revenue | 127,308 | 123,256 | 112,950 | 109,671 | 98,221 | 94,831 | Upgrade
|
| Gross Profit | 175,255 | 178,709 | 166,087 | 156,586 | 151,384 | 146,724 | Upgrade
|
| Selling, General & Admin | 85,920 | 86,880 | 134,072 | 120,610 | 113,586 | 106,599 | Upgrade
|
| Research & Development | 23,899 | 25,416 | - | - | - | - | Upgrade
|
| Other Operating Expenses | 162 | -282 | -3,285 | 101 | -15,710 | 265 | Upgrade
|
| Operating Expenses | 124,296 | 126,524 | 130,787 | 120,711 | 97,876 | 106,864 | Upgrade
|
| Operating Income | 50,959 | 52,185 | 35,300 | 35,875 | 53,508 | 39,860 | Upgrade
|
| Interest Expense | -1,596 | -831 | -476 | -249 | -159 | -190 | Upgrade
|
| Interest & Investment Income | 1,443 | 1,262 | 1,086 | 1,063 | 928 | 947 | Upgrade
|
| Earnings From Equity Investments | -6,002 | -7,575 | -2,362 | -1,604 | -358 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -121 | -121 | -663 | -959 | -910 | -488 | Upgrade
|
| Other Non Operating Income (Expenses) | -197 | -198 | -118 | 371 | -120 | -1,417 | Upgrade
|
| EBT Excluding Unusual Items | 44,486 | 44,722 | 32,767 | 34,497 | 52,889 | 38,712 | Upgrade
|
| Merger & Restructuring Charges | -5,829 | -5,829 | -3,225 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,046 | -1,046 | -228 | 800 | -119 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 738 | 738 | -554 | 412 | -102 | -631 | Upgrade
|
| Asset Writedown | -7,547 | -7,547 | -34,508 | 245 | -40,250 | -5,990 | Upgrade
|
| Legal Settlements | -410 | -410 | -51 | -338 | - | - | Upgrade
|
| Other Unusual Items | -755 | -755 | - | - | - | - | Upgrade
|
| Pretax Income | 29,637 | 29,873 | -5,799 | 35,616 | 12,418 | 32,091 | Upgrade
|
| Income Tax Expense | 3,506 | 3,171 | 9,184 | 8,427 | 5,773 | 10,377 | Upgrade
|
| Earnings From Continuing Operations | 26,131 | 26,702 | -14,983 | 27,189 | 6,645 | 21,714 | Upgrade
|
| Minority Interest in Earnings | 2 | -60 | 35 | 29 | 185 | 1,904 | Upgrade
|
| Net Income | 26,133 | 26,642 | -14,948 | 27,218 | 6,830 | 23,618 | Upgrade
|
| Preferred Dividends & Other Adjustments | 9 | 8 | 7 | 6 | 4 | 2 | Upgrade
|
| Net Income to Common | 26,124 | 26,634 | -14,955 | 27,212 | 6,826 | 23,616 | Upgrade
|
| Net Income Growth | -0.91% | - | - | 298.51% | -71.08% | -26.09% | Upgrade
|
| Shares Outstanding (Basic) | 357 | 367 | 387 | 400 | 399 | 399 | Upgrade
|
| Shares Outstanding (Diluted) | 358 | 368 | 387 | 400 | 400 | 400 | Upgrade
|
| Shares Change (YoY) | -5.60% | -4.98% | -3.26% | 0.02% | 0.03% | -1.75% | Upgrade
|
| EPS (Basic) | 73.26 | 72.59 | -38.60 | 68.07 | 17.09 | 59.16 | Upgrade
|
| EPS (Diluted) | 73.03 | 72.37 | -38.60 | 67.97 | 17.06 | 59.01 | Upgrade
|
| EPS Growth | 4.96% | - | - | 298.44% | -71.09% | -24.77% | Upgrade
|
| Free Cash Flow | 65,871 | 63,330 | 19,870 | 28,699 | 34,669 | 34,123 | Upgrade
|
| Free Cash Flow Per Share | 184.08 | 172.03 | 51.29 | 71.67 | 86.59 | 85.25 | Upgrade
|
| Dividend Per Share | 50.000 | 33.000 | 32.000 | 32.000 | 28.000 | 27.000 | Upgrade
|
| Dividend Growth | 56.25% | 3.13% | 0% | 14.29% | 3.70% | 3.85% | Upgrade
|
| Gross Margin | 57.92% | 59.18% | 59.52% | 58.81% | 60.65% | 60.74% | Upgrade
|
| Operating Margin | 16.84% | 17.28% | 12.65% | 13.47% | 21.44% | 16.50% | Upgrade
|
| Profit Margin | 8.63% | 8.82% | -5.36% | 10.22% | 2.73% | 9.78% | Upgrade
|
| Free Cash Flow Margin | 21.77% | 20.97% | 7.12% | 10.78% | 13.89% | 14.13% | Upgrade
|
| EBITDA | 69,246 | 70,363 | 52,549 | 52,930 | 70,276 | 56,433 | Upgrade
|
| EBITDA Margin | 22.89% | 23.30% | 18.83% | 19.88% | 28.15% | 23.36% | Upgrade
|
| D&A For EBITDA | 18,287 | 18,178 | 17,249 | 17,055 | 16,768 | 16,573 | Upgrade
|
| EBIT | 50,959 | 52,185 | 35,300 | 35,875 | 53,508 | 39,860 | Upgrade
|
| EBIT Margin | 16.84% | 17.28% | 12.65% | 13.47% | 21.44% | 16.50% | Upgrade
|
| Effective Tax Rate | 11.83% | 10.61% | - | 23.66% | 46.49% | 32.34% | Upgrade
|
| Advertising Expenses | - | 18,278 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.